EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Longitudinal Cognitive Assessment After CAR-T Cell Immunotherapy: A Prospective Cohort Study

Evlampia Strongyli iD, Anna Papakonstantinou iD, Christos Demosthenous iD, Zoi Bousiou iD, Anna Vardi, Despina Mallouri, Panagiotis Dolgyras iD, Ioannis Batsis, Paschalis Evangelidis iD, Ioannis Kyriakou, Marianna Masmanidou, Ioannis Giokaris und 9 weitere

Cancers · 01.06.2026 · 18 (11) · 1803

DOI: 10.3390/cancers18111803 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancers, online erschienen am 01.06.2026. Verfasst von Evlampia Strongyli und 20 weiteren Autor:innen. Beteiligte Einrichtung: Endothelial Injury Excellence Centre, Bone Marrow Transplant Unit, Hematology Department, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Cognitive dysfunction represents an emerging concern in chimeric antigen receptor T-cell (CAR-T) therapy recipients, yet longitudinal data using simple, clinically applicable tools are lacking. (2)

Methods

We conducted a single-center prospective cohort study of consecutive adults with hematologic malignancies treated with commercially available CAR-T cell products between May 2023 and November 2025 at our center. Cognitive function was evaluated with the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) at baseline (before the administration of lymphodepleting chemotherapy) (T1), 6 h after infusion (T2), at 3 months (T3), and at 6 months (T4). MoCA scores ≤ 25 and/or MMSE scores ≤ 23 were considered indicative of impaired cognitive function. (3)

Results

Thirty-six patients were enrolled in the present study, while cytokine release syndrome occurred in 33/36 patients (91.7%), and immune effector cell-associated neurotoxicity syndrome of any grade occurred in 23/36 (63.9%). At baseline (T1), cognitive impairment was identified in 12/36 patients (33.3%) by MoCA. Following infusion (T2), 11/35 (31.4%) exhibited cognitive impairment, while baseline cognitive impairment and older age were associated with early post-infusion cognitive dysfunction. Across follow-up (T3 and T4), no significant overall changes were observed in MoCA- or MMSE-defined cognitive status or in total test scores. However, abstraction in MoCA and attention/calculation in MMSE showed time-dependent variation. (4)

Conclusions

These findings support the use of simple longitudinal cognitive assessment in CAR-T recipients.

Schlagwörter

Stichwörter der Autor:innen

CAR-T cell therapyMontreal cognitive assessmentcytokine release syndromeimmune effector cell-associated neurotoxicity syndromemini-mental state examinationneurotoxicity

Autor:innen und Institutionen

  • Endothelial Injury Excellence Centre, Bone Marrow Transplant Unit, Hematology Department, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece.
  • Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
  • 1st Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
  • 3rd Department of Neurology, G. Papanicolaou Hospital, Aristotle University of Thessaloniki, 57010 Thessaloniki, Greece.

ORCID-Profile: Evlampia Strongyli, Anna Papakonstantinou, Christos Demosthenous, Zoi Bousiou, Panagiotis Dolgyras, Paschalis Evangelidis, Maria Gavriilaki, Dimitrios Kazis, Vasilios Kimiskidis, Eleni Gavriilaki

Zitieren

APA

Strongyli, E., Papakonstantinou, A., Demosthenous, C., Bousiou, Z., Vardi, A., Mallouri, D., Dolgyras, P., Batsis, I., Evangelidis, P., Kyriakou, I., Masmanidou, M., Giokaris, I., Gavriilaki, M., Bouinta, A., Yannaki, E., Sotiropoulos, D., Papagiannopoulos, S., Kazis, D., Kimiskidis, V., …, & Gavriilaki, E. (2026). Longitudinal Cognitive Assessment After CAR-T Cell Immunotherapy: A Prospective Cohort Study. Cancers, 18(11), 1803. https://doi.org/10.3390/cancers18111803

Vancouver

Strongyli E, Papakonstantinou A, Demosthenous C, Bousiou Z, Vardi A, Mallouri D, et al. Longitudinal Cognitive Assessment After CAR-T Cell Immunotherapy: A Prospective Cohort Study. Cancers. 2026;18(11):1803. doi:10.3390/cancers18111803

BibTeX
@article{Strongyli2026,
  author = {Strongyli, Evlampia and Papakonstantinou, Anna and Demosthenous, Christos and Bousiou, Zoi and Vardi, Anna and Mallouri, Despina and Dolgyras, Panagiotis and Batsis, Ioannis and Evangelidis, Paschalis and Kyriakou, Ioannis and Masmanidou, Marianna and Giokaris, Ioannis and Gavriilaki, Maria and Bouinta, Asimina and Yannaki, Evangelia and Sotiropoulos, Damianos and Papagiannopoulos, Sotirios and Kazis, Dimitrios and Kimiskidis, Vasilios and Sakellari, Ioanna and Gavriilaki, Eleni},
  title = {Longitudinal Cognitive Assessment After CAR-T Cell Immunotherapy: A Prospective Cohort Study},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1803},
  doi = {10.3390/cancers18111803}
}
Kostenlos starten →